GlassScriptPhysician profile
David A Glaser
NPI 1891807137
$19,686.62
in general payments reported to CMS, 2019-2025
27 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 81% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,647 · 2020: $998 · 2021: $2,226 · 2022: $8,146 · 2023: $2,563 · 2024: $1,556 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,669.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $9,189.60 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,218.14 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,216.03 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,110.93 | 2019-2025 | Vabysmo, Susvimo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $895.10 | 2019-2024 | Arazlo, Siliq, Duobrii |
| Bausch & Lomb Americas INC. | $722.66 | 2022-2025 | Miebo, Envista Envy Iol, Stellaris |
| Apellis Pharmaceuticals, INC. | $660.29 | 2023-2025 | Syfovre |
| Abbvie INC. | $658.63 | 2022-2025 | |
| Alimera Sciences, INC. | $556.04 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $533.10 | 2019-2021 | |
| Astellas Pharma US INC | $458.57 | 2023-2025 | Izervay |
| Allergan, INC. | $389.89 | 2019-2021 | |
| Biotissue Holdings INC. | $335.58 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $216.89 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $209.64 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $199.77 | 2019-2025 | Hydrus Microstent, Ngenuity |
| Harrow Eye, LLC | $165.58 | 2023-2025 | Triesence, Iheezo |
| Eyepoint US, INC. | $163.68 | 2022-2023 | |
| Glaukos Corporation | $159.82 | 2023 | |
| Sight Sciences, INC. | $142.17 | 2024 | Omni Surgical System |
| Ani Pharmaceuticals, INC. | $124.00 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Galderma Laboratories, L.P. | $106.86 | 2025 | |
| Ocular Therapeutix, INC. | $102.86 | 2022 | |
| Mallinckrodt Enterprises LLC | $85.86 | 2019 | |
| Biogen, INC. | $27.13 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech, INC. | $18.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,416.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.